The inauguration of Colorado State University’s Institute for Cannabis Research, Pueblo had none other than professor Raphael Mechoulam from Hebrew University as the key speaker. The Denver Post was at the event.
Professor Mechoulam, an organic chemist, is considered the father of cannabis research. He has been working on it for six decades. His research includes a collection of 400 scientific papers, cited 100,000 times. He is credited with isolating and determining the chemical structure and composition of the major cannabinoids, as well as the synthesis of delta-9 tetrahydrocannabinol, or THC, CBD, or cannabidiol, and cannabigerol, or CBG.
Raphael Mechoulam says CBD not toxic or addictive
Mechoulam said in an interview that he believes CBD should be removed from the list of highly illegal substances such as heroin. The reasons are clear: it is not toxic, is not addictive. It just doesn’t make sense to classify it as such. Once it is removed from the Schedule 1 list, more people will use it, and it could become a major medicine for many conditions.
A selection of our products
CBD for diabetes type 1
Mechoulam highlighted some of his team’s major findings over the years. For instance, delta-8 tetrahydrocannabinol, prevents vomiting when people are treated with chemotherapy for cancer. Also, CBD inhibits the onset of type-1 diabetes in mice, and is an antipsychotic in the treatment of schizophrenia.
The research is there. Some of it has been there for decades. It is a matter of advancing the science into medicine, says Raphael Mechoulam. Unfortunately, little is being done at the moment. He explains that clinical trials are costly, and academics don’t have the resources to complete the long, drawn out process on their own.
Waiting for decades
Raphael Mechoulam has been waiting for more than 10 years for some pharmaceutical company to conduct a trial on CBD for the prevention and treatment of diabetes type-1. In this case, he says it is a real pity that nobody has taken research further. Because there is no difference in mice and humans when it comes to type-1 diabetes, the existing findings are very significant.
Here is an opportunity, and he hopes someone will do a clinical trial soon. Mechoulam believes that CBD can treat diabetes type-1 with no side effects.
The fact that the US Drug Enforcement Administration considers CBD as a schedule 1 substance, the strictest of prohibited substances, is being taken up and challenged on an ongoing basis in the federal appeals court.
Discussion at conferences
550 People attended the Pueblo Cannabis Research Institute’s three-day conference. They came from 10 different countries and 21 US states. The discussion panel covered a wide selection of topics including research, medicine, real estate, taxation, business and health.
CBD as medicine
It is through conferences like these and experts bringing the potential of CBD to the attention of big Pharma and other players that medicines might be produced from cannabis compounds. Let’s hope Professor Mechoulam will soon see the trials that he envisaged decades ago being conducted.